Outcomes research

Circadia Health, Cleveland Clinic Research Collaboration Shows Predictive Power of Continuous Respiratory Monitoring in Prediction of Clinical Deterioration in COVID-19

Retrieved on: 
Wednesday, March 13, 2024
Research, COVID-19, Vital signs, Respiratory rate, Patient, C100, University, SARS-CoV-2, Infection, Cleveland Clinic, Outcome, LOS, FDA, Outcomes research, Health, Frontiers in Medicine

LOS ANGELES, March 13, 2024 /PRNewswire-PRWeb/ -- Continuous monitoring of respiratory rate of patients admitted with Covid-19 using contactless technology demonstrates the ability to predict those at high risk of clinical deterioration up to 24 hours in advance, in a study recently published in Frontiers in Medicine (https://doi.org/10.3389/fmed.2023.1243050).

Key Points: 
  • The study, conducted in collaboration with the Cleveland Clinic, demonstrates Circadia Health's C100 system's ability to offer continuous, contactless respiratory monitoring, predicting clinical deterioration 24 hours in advance and enhancing patient care.
  • In a landmark study, a collaboration between Circadia Health, Cleveland Clinic, and the University of Barcelona utilised the Circadia Health C100 system to monitor patients with respiratory symptoms of SARS-CoV-2 (COVID-19) severe enough to warrant admission to hospital.
  • The C100 system provides continuous respiratory rate monitoring without the need for patient contact, providing respiratory rate data every three seconds.
  • The standard vital sign relating to respiratory function, intermittent respiratory rate measurement, was not predictive of subsequent decline.

The AI Revolution in Clinical Research: Next-Gen Precision Patient Matching, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, EMR, GSK, File association, Artificial intelligence, Pathology, Outcomes research, Chronic obstructive pulmonary disease, Documentation, Breast, TNBC, Patient, MPH, Clinical trial, Research, COPD, Medical device

TORONTO, Feb. 29, 2024 /PRNewswire-PRWeb/ -- The convergence of artificial intelligence (AI) and electronic medical record (EMR) data has brought unprecedented precision and speed to finding patients for clinical trials, real-world evidence studies and even treatments in a clinical setting. In this webinar, the featured speakers will explore innovative ways in which life sciences companies are using AI to find patients more precisely, prioritize patients for research based on therapy-specific criteria and collaborate with sites to quickly access EMR data.

Key Points: 
  • In this free webinar, learn how to use AI to mine structured and unstructured electronic medical record (EMR) data to precisely find patients for clinical trials and real-world evidence studies.
  • The featured speakers will discuss case studies on precisely identifying patients with chronic obstructive pulmonary disease (COPD) exacerbations and identifying and prioritizing patients for a heart device clinical trial.
  • TORONTO, Feb. 29, 2024 /PRNewswire-PRWeb/ -- The convergence of artificial intelligence (AI) and electronic medical record (EMR) data has brought unprecedented precision and speed to finding patients for clinical trials, real-world evidence studies and even treatments in a clinical setting.
  • Register for this webinar today to gain insights into the benefits of AI-driven patient matching as well as mining of deep, real-time EMR data.

HeartSciences Expands its Scientific Advisory Board

Retrieved on: 
Monday, February 12, 2024
Bangladesh Technical Education Board, Accreditation, HSCS, American Society of Echocardiography, Algorithm, Research, American Heart Association, Artificial intelligence, AI, Intelligence, Assistant, FDA, Outcomes research, Diagnostic medical sonography, ECG, Education, Society, GE HealthCare, American College, Journal, Machine learning, Harvard Medical School, ACC, Commission, Medical device

Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

Key Points: 
  • Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
  • Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medicine at Mount Sinai, New York.
  • Dr. Strom has expertise in AI-based medical devices and is a consultant to GE Healthcare, Phillips Healthcare, and Edwards Life Sciences.
  • HeartSciences is an innovator in this field, and I look forward to helping them unleash the potential power of AI-powered ECGs to help clinicians deliver timely and optimal care.

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Retrieved on: 
Thursday, October 26, 2023
Nexus, Patient, FDA, Academy of Managed Care Pharmacy, Research, Standard of care, Cyclophosphamide, Food, Outcomes research, ClinicoEconomics and Outcomes Research, Treatment, NS, Adrenocorticotropic hormone (medication), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, D20, QALY, Poster, Nephrotic syndrome, Congenital nephrotic syndrome, Adrenocorticotropic hormone, Sarcoidosis, Chlorambucil, Rituximab, Symphony, ICER, SOC, Calcineurin, AMCP, Azathioprine, Diagnosis, Proteinuria, Pharmaceutical industry, Medical imaging, Mallinckrodt

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health economics outcomes research on Acthar® Gel (repository corticotropin injection) for patients with advanced symptomatic sarcoidosis and nephrotic syndrome (NS)1,2 at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 in Orlando, FL October 16-19, 2023.

Key Points: 
  • Patients were monitored at the end of a three-month cycle for a partial or complete response.
  • The full data manuscript from this study was published in ClinicoEconomics and Outcomes Research on October 17, 2023.
  • "We are pleased to have shared our latest health economics research on Acthar Gel.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to Acthar.

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)

Retrieved on: 
Tuesday, October 10, 2023
Narrative, RA, Adrenocorticotropic hormone, Health, Literature review, Food, Polymyositis, Dermatomyositis, MS, Abstract, Autoimmunity, Length of stay, Spasm, Clinical, Manuscript, Copyright in Historical Perspective, MOA, Nephrotic syndrome, Rheumatoid arthritis, FDA, Proteinuria, RCI, Patient, ClinicoEconomics and Outcomes Research, History, Literature, Lupus, Multiple sclerosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sarcoidosis, Outcomes research, Inflammation, SLE, Pharmaceutical industry, Medical device, Mallinckrodt, Adrenocorticotropic hormone (medication)

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of Acthar Gel for appropriate patients across a range of FDA-approved autoimmune and inflammatory disease indications.1,2 

Key Points: 
  • Mallinckrodt's health economics manuscript titled "Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence" was published on June 24, 2023 in ClinicoEconomics and Outcomes Research.
  • Acthar is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.
  • Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune disorders and medical conditions known to cause inflammation.3
    Please see indications and Important Safety Information below.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical outcomes may not be solely attributable to Acthar.

Healthcare AI Leader ClosedLoop Launches Two First-of-Their-Kind Data Science Products for Value-Based Care

Retrieved on: 
Tuesday, September 19, 2023
Health Technology, Telemedicine, Virtual Medicine, Data Management, Technology, Pharmaceutical, Practice Management, Apps, Applications, Managed Care, General Health, Artificial Intelligence, Other Technology, Science, Software, Other Science, Health, ACO, Software as a service, CMS, BCDA, Outcomes research, Acos, Organization, Medicare, CCM, Explainable artificial intelligence, Population health, Patient, Algorithm, Outcome, Evaluation, Blackbox, Accountable care organization, Pharmaceutical industry, KLAS

ACO-Predict offers the same algorithms ClosedLoop used to win both the CMS AI Challenge and Best in KLAS recognition in 2021 and 2022.

Key Points: 
  • ACO-Predict offers the same algorithms ClosedLoop used to win both the CMS AI Challenge and Best in KLAS recognition in 2021 and 2022.
  • When combined with CMS’s recently updated Beneficiary Claims Data API (BCDA) data feeds, ACO-Predict provides turnkey risk stratification for Complex Care Management (CCM) programs free of charge to all Medicare ACOs.
  • Complex Care Management programs are one of the essential tools ACOs use to reduce costs and improve outcomes in their Medicare populations.
  • “To succeed in value based care, organizations need to do two things,” said Andrew Eye, Co-Founder and CEO of ClosedLoop.

Chasing Breakthrough Innovation in a Time of Uncertainty With Insights from McKinsey & Company

Retrieved on: 
Tuesday, September 19, 2023
Chief technology officer, PTC Therapeutics, Senior, Doctor of Philosophy, Advocacy, Outcomes research, Horizon Therapeutics, Health care, PTC, Policy, Senior advisor, Ernst & Young, Osteonecrosis of the jaw, Bristol Myers Squibb, Insming, Cross-cultural communication, Director of Communications (Office of the Prime Minister), Indivior, Digital, Therapy, Pharmaceutical industry, Management

TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott. The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.

Key Points: 
  • Friday, October 6, 2023 • 7:30 a.m.-4:00 p.m. Bridgewater Marriott, 700 Commons Way, Bridgewater
    TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott.
  • The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.
  • "As the policy environment churns and investment in biopharma fluctuates, questions are being raised about the future of innovation for our industry," said BioNJ President and CEO, Debbie Hart.
  • "The C-Suite Summit allows stakeholders to come together for an open conversation on where the greatest opportunities lie and how to best prepare for and shape the next paradigm in life sciences and medical discovery."

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Linda, Partnership, University, Pediatrics, Therapy, NOD, Outcomes research, Pediatric endocrinology, Immune tolerance, Pancreas, University of California, Research, Multiple sclerosis, Inflammation, Autoimmunity, Assistant, TCR, Harvard Medical School, ITN, Behavior, Indiana University School of Medicine, Patient, Division, Lymph, Insulitis, Benaroya Research Institute, Endocrinology, Biology, Joslin Diabetes Center, Pharmaceutical industry, Nursing, T1D, Regulatory T cell, Medicine

“We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.

Key Points: 
  • “We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.
  • Additional non-clinical studies have established the role of Tregs in suppressing β-cell injury, a further potential benefit of the approach.
  • “This second program expands the scope of our pioneering Treg cell-based approach to patients with T1D.
  • This group brings deep expertise in T1D pathogenesis and the clinical development of novel therapeutics.

Practical Pain Management and Society of Pain & Palliative Care Pharmacists Foundation Announce Second Annual Fudin Award for Mentorship

Retrieved on: 
Thursday, July 6, 2023
Lewis & Clark College, Society, Doctor of Pharmacy, University, McPherson, Education, PPM, Outcomes research, State University of New York Upstate Medical University, Mentorship, Patient, Medicine, Doctor of Philosophy, Maryland School, Pain, Pharmacist, Student, Professor, Stratton, Trustee, Humour, Outline of health sciences, Pain management, Education minister, FCCP, Albany College of Pharmacy and Health Sciences, American Cancer Society, Knowledge, Chronic pain, Memory, Nursing, Medical device, Pharmacy, Palliative care

ARLINGTON, Va., July 6, 2023 /PRNewswire/ -- Practical Pain Management (PPM), a leading digital health brand serving  pain-treating clinicians, and the Society of Pain and Palliative Care Pharmacists Foundation, today announced that Mary Lynn McPherson, PhD, PharmD, has been awarded the Fudin Award for Mentorship.

Key Points: 
  • ARLINGTON, Va., July 6, 2023 /PRNewswire/ -- Practical Pain Management (PPM), a leading digital health brand serving  pain-treating clinicians, and the Society of Pain and Palliative Care Pharmacists Foundation, today announced that Mary Lynn McPherson, PhD, PharmD, has been awarded the Fudin Award for Mentorship.
  • "Her work demonstrates her dedication to the advancement of palliative care, inspiring students to follow in her footsteps," said Dr. Jeff Gudin, PPM editor-at-large.
  • For decades, she has educated on pain management and palliative care at both local and national levels.
  • Dr. Fudin was a founding member and inaugural Trustee for the Society of Pain and Palliative Care Pharmacists and he was co-editor of PPM.

Emergency department overcrowding: Can AI, predictive modeling and simulation fix it?

Retrieved on: 
Thursday, July 6, 2023
Pressure, Communication, University, College, Bed, Nursing, Engineering, EMR, Outcomes research, ARCHES, Grainger College of Engineering, Kang, The College of Medicine, COVID-19, Sister, Fred Hutchinson Cancer Research Center, Research, Multimedia, OSF HealthCare, University of Illinois Urbana-Champaign, Doctor of Philosophy, Forecasting, Museum, Hospital, Illinois College, MD, Patient, OSF, Machine learning, Missionary, University of Illinois College of Medicine, Champaign–Urbana metropolitan area, Physician, Virtual reality, Data, Weather, Applied science, Third order, Health, ED, UIUC, Community health, Safety, Management

PEORIA, Ill., July 6, 2023 /PRNewswire/ -- It seems almost everyone has a story about how long they had to wait to receive care in an emergency department due to overcrowding. In fact, research shows patient congestion is one of the main factors threatening efficiency, safety and quality of care.

Key Points: 
  • William Bond, MD, is an emergency department (ED) physician at OSF HealthCare Saint Francis Medical Center in Peoria, Illinois.
  • He also directs simulation research at Jump Simulation , a collaborative effort between OSF and the University of Illinois College of Medicine Peoria (UICOMP).
  • The project is called: STREAM-ED: Simulation to Refine, Enhance and Adapt Management of Emergency.
  • They'll also use data about physical resources and providers, including nurses and technicians who deliver assessments or care in different pods within the emergency department.